German-based global pharma giant STADA has announced the acquisition of the pharmaceutical business of Biopharma, one of Ukraine’s key pharmaceutical producers.
The deal, which is set to close by the end of December 2019, includes Biopharma’s modern production facilities in the Kyiv region. The purchase, for an undisclosed fee, represents a significant landmark for the Ukrainian pharmaceutical industry and is one of the largest international investments in Ukraine in recent years.
“We see great potential in the Ukrainian market. With this acquisition, we will become an important player in the Ukrainian pharma market with a strong local production footprint,” commented STADA CEO Peter Goldschmidt.
Source: Ukraine Invest